SiSaf Ltd
Richard Scarrott has a strong background in finance and business management. Richard most recently served as the Chief Financial Officer at SiSaf Ltd, a company focused on RNA therapeutics. Prior to that, they held various positions at HIPPO™, including Finance and Commercial Director, Finance Director and COO, and Finance Director. Richard also worked as the Chief Financial Officer at Norwood Immunology Limited, an AIM listed biotech group. Earlier in their career, they worked as a Consultant at RJS Associates, advising pharma and healthcare companies on business plans and strategy. Richard began their career at Arthur Andersen, where they spent 14 years in Corporate Finance, specializing in mergers and acquisitions and fundraising.
Richard Scarrott completed their Bachelor of Science degree with honors in Management and Business at Aston University from 1986 to 1990.
This person is not in any offices
SiSaf Ltd
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.